Yingfeng Huang

CEO at CytoCares (Shanghai) Inc.

Presenter

CytoCares is a leading cell engager therapeutics company developing innovative approaches to address cancer and autoimmune diseases. CytoCares has created innovative T cell, NK cell and macrophage engager platforms with the potential to improve the lives of thousands of patients. CytoCares has developed 10+ clinical and preclinical programs targeting hematologic tumors, solid tumors, and autoimmune diseases with high unmet need. The first therapy from its TriTE™ technology platform: CC312, a next generation CD19 trispecific T cell engager that stands out, as the first of its kind with key advantages versus existing cell therapies and TCEs. It features a unique trispecific CD3xCD28xCD19 structure driving two signal co-stimulation absent from existing TCEs that is critical for greater T cell activation and proliferation as well as longer term T cell response. The IND application of CC312 for B-cell Hematologic Malignancies was granted approved by the FDA and NMPA. In August 2024, CC312 was approved for clinical use with an indication for the SLE by NMPA. CC312 shows the safe tolerance and some potential clinical efficacy in clinical study of B cell lymphoma. In addition to oncology, CC312 possesses immense promise in autoimmune disease. The latest SLE clinical data show that CC312 has excellent tolerability and safety. In multiple patients with moderate-to-severe relapsed/refractory SLE, effective B-cell depletion in peripheral blood was observed within one week of treatment. By the end of dosing, significant reductions in SLEDAI-2K scores were recorded, along with marked improvements in key clinical markers such as anti-dsDNA antibodies, proteinuria, pyuria, and autoantibodies, achieving SRI-4 response rates. Furthermore, both B-cell subset depletion (memory B cells, plasmablasts, etc.) and clinical efficacy exhibited clear dose-dependent effects, with near 100% B-cell depletion and outstanding clinical responses consistently observed in mid-dose groups.